Pressure BioSciences, Inc. Announces Move to New Corporate Offices

SOUTH EASTON, Mass., March 10 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) today announced that it has moved its corporate offices to 14 Norfolk Avenue in South Easton, Massachusetts. This move was necessary to accommodate the Company's transition from an early-stage, research and development company to a fully commercial operation. Richard T. Schumacher, PBI's Founder, President, and CEO commented: "We now have approximately 5,500 square feet, with sufficient office, conference, engineering lab, and storage space to allow us to better develop our infrastructure to support our PCT product commercialization. In addition, the 18 month lease, with equal term extension, gives us the financial flexibility we require as we continue to grow our business and carefully manage our financial resources". The Company's primary research and development facility continues to be located at 6 Gill Street in Woburn, MA.

    Corporate address:
    Pressure BioSciences, Inc
    14 Norfolk Avenue
    South Easton, MA 02375
    (t) (508) 230-1828
    (f) (508) 230-1829

    Research and Development Center
    Pressure BioSciences, Inc
    6 Gill Street, Suite H
    Woburn, MA 01801
    (t) (781) 932-9477
    (f) (781) 932-9294

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to, risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

    Visit us at our website http://www.pressurebiosciences.com

    Investor Contacts:
    Richard T. Schumacher, President & CEO          Pressure BioSciences, Inc.
    Edward H. Myles,
    Senior Vice President of Finance & CFO                    (T) 508-230-1828

SOURCE Pressure BioSciences, Inc.

Released March 10, 2008